Screener
Phathom Pharmaceuticals, Inc. PHAT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324867
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Operating lease liabilities, current | 670 | 648 |
| Current portion of revenue interest financing liability | 37,283 | 27,249 |
| Other current liabilities | — | 7,500 |
| Total current liabilities | 153,777 | 132,044 |
| Long-term debt, net of discount | 164,587 | 209,087 |
| Revenue interest financing liability | 347,629 | 350,122 |
| Operating lease liabilities | 1,855 | 2,065 |
| Other long-term liabilities | 3,500 | 4,000 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Phathom Pharmaceuticals, Inc.'s total current liabilities?
- Phathom Pharmaceuticals, Inc. (PHAT) reported total current liabilities of $153.78M in Q2 2026.
- How has Phathom Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s total current liabilities increased by 67.5% year-over-year, from $91.82M to $153.78M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s total current liabilities has grown at a 18.9% compound annual growth rate (CAGR), from $55.52M to $132.04M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Phathom Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude